| |
|
Form Serial Number: |
DA20230721E00350
|
| 1.
Date of relevant event: |
11/07/2023
(dd/mm/yyyy)
|
| 2.
Date when director became aware of the relevant event/ interest in the shares (if later): |
(dd/mm/yyyy)
|
| 3.
Stock code: |
06990 |
| 4.
Name of listed corporation: |
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. - B - H Sh |
| 5.
Class of shares: |
Others |
| 6.
Number of issued shares in class: |
155,138,328 |
| 7.
Name of director (English) as printed on HKID Card/Passport: |
| (Surname) |
LIU |
| (Other names) |
Gexin |
|
|
|
| 10.
Name of director (Chinese): |
刘革新 |
| 11.
Chinese Character Code as printed on HKID Card: |
|
| |
| 24.
Details of relevant event: |
|
|
Brief description of relevant event
|
Capacity in which shares were/are held
|
Number of shares bought/sold or involved
|
Currency of transaction |
On Exchange
|
Off Exchange
|
|
Before relevant event
|
After relevant event
|
Highest price (per share)
|
Average price (per share)
|
Average consideration (per share)
|
Consideration code
|
| Long position |
| 1701 | Miscellaneous
On listing of the corporation or a class of shares of the listed corporation |
|
|
| 2201 | Interest of corporation controlled by you |
|
136,555,685 |
|
|
|
|
|
| Short position |
|
|
|
|
|
|
|
|
|
| |
|
| 25.
Total shares in listed corporation immediately before the relevant event: |
| | Total number of shares | Percentage figure (%) |
| | | |
|
| |
| 26.
Total shares in listed corporation immediately after the relevant event: |
| | Total number of shares | Percentage figure (%) |
| Long position | 136,555,685 | 88.02 |
|
| |
| 27.
Capacity in which interests disclosed in Box 26 are held: |
| Code describing capacity | Number of shares |
| 2201 | Interest of corporation controlled by you |
| |
|
| |
| 28.
Further information in derivative interests in listed corporation : |
| Derivatives code |
Exercise period (dd/mm/yyyy) |
Consideration - if derivatives granted by listed corporation |
Number of shares |
| | | Begins | Ends | Currency | Price for grant | Currency | Exercise price | Currency | Price on assignment | |
| | | | | | | | | | | |
|
| |
| 29.
Further information in relation to interests of children under 18 and/or spouse: |
| Child/Spouse | Name of child/spouse | Number of shares |
| | |
|
| |
| 30.
Further information in relation to interests of corporations controlled by Director: |
| Name of controlled corporation | Address and place of incorporation | Name of controlling person | % control | Direct interest (Y/N) | Number of shares |
| 四川科伦药业股份有限公司 | 中国成都市新都卫星城工业开发区南二路 （中国） | 刘革新 | 25.70 | Y | |
| 四川科伦药业股份有限公司 | 中国成都市新都卫星城工业开发区南二路 （中国） | 刘革新 | 25.70 | N | |
| 成都科伦晶川科技有限公司 | 中国成都市温江区成都海峡两岸科技产业开发园新华大道666号（中国） | 四川科伦药业股份有限公司 | 100.00 | N | |
| 成都科伦汇才企业管理中心(有限合伙) | 中国成都市温江区成都海峡两岸科技产业开发园新华大道666号（中国） | 成都科伦晶川科技有限公司(作为普通合伙人) | 100.00 | Y | |
| 成都科伦汇德企业管理中心(有限合伙) | 中国成都市温江区成都海峡两岸科技产业开发园新华大道666号（中国） | 成都科伦晶川科技有限公司(作为普通合伙人) | 100.00 | Y | |
| 成都科伦汇能企业管理中心(有限合伙) | 中国成都市温江区成都海峡两岸科技产业开发园新华大道666号（中国） | 成都科伦晶川科技有限公司(作为普通合伙人) | 100.00 | Y | |
| 成都科伦汇智企业管理中心(有限合伙) | 中国成都市温江区成都海峡两岸科技产业开发园新华大道666号（中国） | 成都科伦晶川科技有限公司(作为普通合伙人) | 100.00 | Y | |
|
| |
| 31.
Further information in relation to interests held by Director jointly with another person: |
| Name of joint shareholder | Address | Number of shares |
| | |
|
| |
| 32.
Further information from a director who is a trustee, or beneficiary of a trust, or a person who has set up a Discretionary Trust: |
| Names of Trust | Address | Status code | Number of shares |
| | | |
|
| |
| 33.
Further information from a party to an agreement under Section 317 (Please see Notes for further information required): |
| Names of other parties | Address | Number of shares |
| | |
| Total number of shares in which a director is interested under sections 317 and 318 | |
|
| |
| 34.
Supplementary information: |
有关方格5而言，“其他”指科伦博泰的非上市股份，包括149,589,850股内资股及5,548,478股非上市外资股。有关方格30而言，(1) 刘革新先生持有科伦药业约25.70%股权，有能力对科伦药业拥有控制权。故刘革新先生被视为于科伦药业所持有的股份中拥有权益。(2) 科伦药业直接持有115,555,685股内资股。(2) 科伦晶川为科伦药业的全资子公司。(3) 科伦汇才、科伦汇德、科伦汇能及科伦汇分别持有5,250,000股内资股。根据科伦晶川(作为普通合伙人)分别与科伦汇才、科伦汇德、科伦汇能及科伦汇智的有限合伙人签订的合伙协议，科伦晶川(作为普通合伙人)可分别行使科伦汇才、科伦汇德、科伦汇能及科伦汇智持有股份所附带的表决权。故科伦晶川被视为于科伦汇才、科伦汇德、科伦汇能及科伦汇智所持有的股份中拥有权益。请参阅科伦博泰2023年6月29日的招股章程。
|
| 35.
Log/Serial Number of the previous form: |
|
| 36.
Number of concert party document(s) under section 317 attached/uploaded: |
|
|
Date of filing this Form 3A: |
21/07/2023
(dd/mm/yyyy)
|
| |